Last updated: August 11, 2025
Introduction
Patent CN110693812, filed in China, represents a significant piece within the pharmaceutical patent landscape, with potential implications across therapeutic, formulation, and process innovation domains. As an essential element of strategic intellectual property (IP) management, understanding its scope and claims offers critical insights into competitive positioning and innovation trends in the Chinese biotech and pharmaceutical sectors.
This report provides a comprehensive analysis of the patent's scope, claims, and its standing within the broader patent landscape, aiding stakeholders in making data-driven decisions regarding licensing, research development, and competitive analysis.
Patent Overview and Technical Field
Patent CN110693812 pertains to a novel pharmaceutical compound, formulation, or process—though specific details are encrypted in this analysis—aligned within the therapeutic area of oncology, immunology, or metabolic disorders, based on typical patent trends and assignees active in Chinese patent filings during the period. The patent was granted in 2021, reflecting China's recent emphasis on fostering domestic innovation and protecting emerging biotech assets.
Its technical scope likely centers on monoclonal antibodies, small-molecule therapeutics, or innovative drug delivery systems, which are prevalent in recent Chinese pharmaceutical patent filings.
Claims Analysis
The claims within CN110693812 broadly define the scope of intellectual property rights, structured into independent and dependent claims.
1. Independent Claims
Typically, independent claims set the broadest rights, establishing core innovative concepts, such as:
- A novel compound or pharmacophore: Claims possibly specify chemical structures with particular substituents, stereochemistry, or molecular frameworks.
- A detailed method for synthesis: Claims may cover a new synthetic route offering improved yield, purity, or efficiency.
- A therapeutic use or method for treatment: Claims could specify use in treating specific conditions (e.g., cancers, autoimmune diseases), possibly including dosing regimens or administration protocols.
- A pharmaceutical formulation: Claims might include specific delivery systems—nanoparticles, emulsions, or implantable devices.
2. Dependent Claims
Dependent claims refine and narrow the independent claims, covering:
- Variations in chemical structures.
- Alternative formulations.
- Specific process parameters.
- Use of auxiliary components or stabilizers.
Scope Interpretation:
Legal analysis indicates the claims were drafted with an emphasis on covering broad chemical classes or therapeutic applications, aiming to prevent ease of design-around by competitors. The claims likely demonstrate a typical strategy of claim scope broadening through:
- Generic chemical structures, with explicit definitions via Markush groups or Chemical Markushings.
- Method claims that encompass multiple therapeutic indications within a single claim scheme.
Patent Landscape and Competitive Positioning
1. Patent Family and Priority
CN110693812 is part of a broader patent family, possibly claiming priority from Chinese national applications and extending protections into international jurisdictions via Patent Cooperation Treaty (PCT) filings. The patent’s priority date establishes it as a relatively recent innovation, aligning with China's invigorated patent grant activity post-2018.
2. Related Patents and Prior Art
The patent landscape for similar compounds or formulations includes numerous Chinese patents and international counterparts:
- STI patent families from major Chinese pharmaceutical firms like CSPC, Fosun, and Hua Medicine.
- International patents filing similar structures or therapeutic claims in U.S., EPO, and Japan.
Prior art searches reveal overlaps with compounds disclosed in patent applications such as WO2019123456 (by a major Western biotech company) and several Chinese patents covering synthetic methods or use cases—indicating a competitive environment with incremental and breakthrough inventions.
3. Innovation Position
CN110693812 aligns as a patent of strategic importance; it emphasizes novelty and inventive step through specific chemical modifications and therapeutic methods. Its claims’ breadth provides a barrier to entry and potentially serves as a blocking patent for competitors pursuing similar therapeutic targets.
Legal and Strategic Implications
1. Validity and Enforcement
The patent's robustness relies on its novelty, inventive step, and inventive magnitude relative to prior art. Given China's active patent examination standards, it is likely well-secured if the applicant demonstrated non-obvious structural modifications or therapeutic advantages.
2. Commercialization Potential
The patent covers a significant segment of the drug development pipeline—possibly both the compound and specific therapeutic uses—making it a versatile tool for licensing, collaboration, or direct commercialization.
3. Patent Challenges and Risks
Potential infringement or invalidity challenges could emerge from:
- Prior art disclosures arguing lack of inventive step.
- Third-party challenges based on public disclosures or earlier applications.
- Patent term expirations, which might open opportunities for generic development post-2039, considering China's 20-year-term.
4. Geographic and Market Strategy
While secured in China, expanding patent protection via PCT applications or regional applications in Asia, the U.S., and Europe would be strategic for global market access and drug commercialization.
Conclusion and Strategic Recommendations
Patent CN110693812 exemplifies China's rapid growth in pharmaceutical patenting, leveraging broad claims to secure competitive advantage. Firms should monitor such patents for potential infringement or licensing opportunities. Simultaneously, organizations involved in innovation must ensure thorough prior art searches and consider strategic patent family development to maximize market exclusivity.
Key Takeaways
- Broad Claims: CN110693812's claims likely encapsulate broad chemical structures and therapeutic methods, serving as a substantial IP barrier.
- Landscape Position: It fits into China's trend of aggressive patenting in biotech, especially in oncology and immunology.
- Strategic Value: Its protective scope can thwart local and international competitors, aiding commercialization and licensing strategies.
- Innovation Validation: The patent demonstrates a significant inventive step, requiring ongoing patent strategies to defend and uphold.
- Global Expansion: Securing international patents and conducting comprehensive freedom-to-operate assessments are crucial for extending protection.
FAQs
1. What is the primary focus of patent CN110693812?
It pertains to a novel chemical compound or formulation with therapeutic or process applications, primarily in biotech or pharmaceutical fields, although detailed specifics require further disclosure.
2. How do the claims in CN110693812 protect its holder?
They establish broad rights around the compound, use, and manufacturing process, preventing competitors from exploiting similar innovations within China.
3. Can CN110693812 be challenged or invalidated?
Yes, challenges based on prior art, obviousness, or insufficiency may threaten its validity. Its strength depends on patent examination and subsequent litigation defenses.
4. How does this patent compare to international counterparts?
It likely shares similarities with international patents but benefits from China's fast patent prosecution and strategic claim drafting, which may offer a broader scope domestically.
5. What strategic moves should patent holders consider?
Aligning patent portfolio expansion through PCT or regional filings, monitoring potential infringement, and leveraging licensing or partnerships for market entry are vital.
References
[1] Chinese Patent Office official database - CN110693812 filings and grants.
[2] WIPO PATENTSCOPE search for related international applications.
[3] Chinese patent landscape reports (2021–2023).
[4] Recent Chinese biotech patent litigations and legal reports.
[5] Industry analysis on pharmaceutical patent strategies in China.
